PLUS THERAPEUTICS, INC. - FORM S-1/A - EX-23.1 - CONSENT OF KPMG LLP INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - May 10, 2016

Attached files

file filename
S-1/A - CYTORI THERAPEUTICS FORM S1 - PLUS THERAPEUTICS, INC.forms1.htm
EX-99.1 - FORM OF INSTRUCTION RGHTS CERTIFICATES - PLUS THERAPEUTICS, INC.ex99_1.htm
EX-99.5 - FORM OF BENEFICIAL OWNER ELECTION FORM - PLUS THERAPEUTICS, INC.ex99_5.htm
EX-4.28 - FORM OF WARRANT AGREEMENT BETWEEN CYTORI THERAPEUTICS INC AND BROADRIDGE CORPORATE ISSUER SOLUTIONS INC - PLUS THERAPEUTICS, INC.formofwarrantagreement.htm
EX-99.3 - FORM OF LETTER TO BROKER, DEALER, BANKS AND OTHER NIMINEES - PLUS THERAPEUTICS, INC.ex99_3.htm
EX-99.6 - FORM OF NIMINEE HOLDER CERTIFICATION - PLUS THERAPEUTICS, INC.ex99_6.htm
EX-4.27 - FORM OF SERIES R WARRANT UNDERLYING THE UNITS - PLUS THERAPEUTICS, INC.formofseriesrwarrant.htm
EX-99.4 - FORM OF BROKER LETTER TO CLIENTS WHO ARE BENEFICIAL HOLDERS - PLUS THERAPEUTICS, INC.ex99_4.htm
EX-4.26 - FORM OF NON TRANSFERABLE SUBSCRIPTION RIGHTS CERTIFICATE - PLUS THERAPEUTICS, INC.fomofnontransferable.htm
EX-8.1 - TAX OPINION OF DLA PIPER LLP US - PLUS THERAPEUTICS, INC.taxopinionofdlapiperllp.htm
EX-5.1 - OPINION OF DLA PIPER LLP US - PLUS THERAPEUTICS, INC.opinionofdlapiper.htm
EX-1.1 - FORM OF DEALER MANAGER AGREEMENT BY AND BETWEEN CYTORI THERAPEUTICS, INC MAXIM GROUP LLC - PLUS THERAPEUTICS, INC.formofdealermanager.htm
EX-99.2 - FORM OF LETTER TO SHAREHOLDERS WHO ARE RECORD HOLDERS - PLUS THERAPEUTICS, INC.ex99_2.htm

EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
 Cytori Therapeutics, Inc.:
We consent to the use of our reports with respect to the consolidated financial statements, the accompanying schedule of valuation and qualifying accounts and the effectiveness of internal control over financial reporting incorporated by reference herein and to the reference to our firm under the heading "Experts" in the prospectus.
Our report dated March 11, 2016 contains an explanatory paragraph that states that the Company's recurring losses from operations, and liquidity position raises substantial doubt about its ability to continue as a going concern.  The consolidated financial statements and financial statement schedule do not include any adjustments that might result from the outcome of that uncertainty.
/s/ KPMG LLP
San Diego, California
 May 10, 2016

Stock widget

Investing forum

PLUS THERAPEUTICS, INC. Reports